SARS-CoV-2-related chilblains

Abstract

A healthy 16-year-old girl presented with a 2-week history of painful red-violaceous papules to her left third toe, right fifth toe and right index finger (Figure 1). She had no history of exposure to cold or damp and no systemic symptoms, but she lived with an asymptomatic front-line health care worker. We diagnosed chilblains and investigated for systemic causes.Our investigation for secondary chilblains included a complete blood count, liver studies, and determination of the levels of creatinine, antinuclear antibody, extractable nuclear antigen, double-stranded DNA, anticardiolipin antibody, lupus anticoagulant, anti-β2-glycoprotein, complement, coagulation, D-dimer, cryoglobulins, cryofibringens and cold agglutinins, all of which gave results that were negative or within normal limits. A punch biopsy showed superficial and deep dermal lymphocytic inflammation with subepidermal edema. Because chilblains has been associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, 1-3 we collected an oropharyngeal swab for polymerase chain reaction testing, which gave a negative result. However, measurement of IgG and IgA antibody levels by enzyme-linked immunosorbent assay (EURO-IMMUN) to SARS-CoV-2 gave positive results. We diagnosed SARS-CoV-2-related chilblains. We encouraged our patient to self-isolate, avoid cold and damp conditions, and apply a corticosteroid topically to the symptomatic sites. Her lesions resolved over the next 3 weeks.Chilblains, also known as pernio, refers to a superficial inflammatory cutaneous disease triggered by cool or damp environments. Chilblains is categorized as primary (idiopathic) or secondary to autoimmune, hematologic or autoinflammatory diseases. 4 As chilblains is often unrecognized, its incidence remains unknown. It more commonly affects women, and idiopathic chilblains is more common in children, whereas secondary chilblains usually presents in mid-adulthood. 4 Chilblains has been reported as a cutaneous, often late, manifestation of coronavirus disease 2019 (COVID-19) ("COVID toes"). [1][2][3] It can be the sole manifestation of SARS-CoV-2 infection. 1,2 The average reported age in the 2 case series of patients with COVID-19-related chilblains was 14 and 32 years. 1,3 Because the virus may have cleared by the time of cutaneous presentation, clinicians should consider antibody testing to identify SARS-CoV-2. Although chilblains is considered to be a late manifestation of COVID-19, 1 more evidence regarding its presentation and the risk of transmission of SARS-CoV-2 is required. As a precaution, all patients with suspected SARS-CoV-2-related chilblains should be encouraged to self-isolate.

“COVID toes”: A meta‐analysis of case and observational studies on clinical, histopathological, and laboratory findings

“…Five (2.6%) reported using no medications. Twenty‐four (12.8%) reported the use of various medications: nonspecific topical corticosteroid, 4 heparin gel, 5 topical clobetasol, 6 nitroglycerin gel, 7 topical triamcinolone, 6 topical clotrimazole, 6 nonspecific topical antibiotic, azithromycin, 8 , 9 hydroxychloroquine, 8 , 9 oral antihistamine, nonspecific oral corticosteroid, aspirin, 10 gabapentin, 10 enoxaparin, 7 heparin, 11 low‐molecular‐weight heparin, 12 and tocilizumab. 8 …”

Beau lines associated with COVID-19

“…1 Some of these findings, such as the vesicular eruption, appear early in the disease course; others are seen later, such as the chilblain pattern. 2 Beau lines are transverse grooves in the nail plate that result from transient interruption of the growth of the proximal nail matrix. 3 They are often noticed 2-3 weeks after a systemic insult and their appearance parallels the length of time needed for the nail to grow past the proximal nailfold.…”

A visually striking case of primary acrocyanosis: A rare cause of the blue digit

“…Pernio-like lesions of COVID-19, also known as chilblains, a novel cause of the blue digit, can be characterized by rapid onset, itching, pain and tenderness and quick improvement with re-warming, very similar to primary acrocyanosis [ 1 ]. Chilblains have been reported in the setting of cold weather as well as in the setting of COVID-19 infection but unlike primary acrocyanosis are associated with pain and improvement with Nifedipine [ 1 , 5 ]. Primary acrocyanosis is a diagnosis of exclusion, however once its possibility has been raised, secondary causes of acrocyanosis including connective tissue diseases, hypoxemia and drug exposures among other conditions should be ruled out [ 1 , 3 ].…”

“…Additionally, we propose that a nasopharyngeal swab be sent to differentiate primary acrocyanosis from the novel COVID-19 associated chilblains, given the similarity in presentation [ 1 , 4 ]. As a precaution, all patients with suspected COVID-19 infection should be instructed to self-isolate [ 5 ]. Once the diagnosis of primary acrocyanosis has been made conservative management including counselling on lifestyle modifications including smoking cessation, avoiding cold weather and using insulated clothing to improve local circulation and decrease arteriospasm should be initiated [ 1 ].…”